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Conclusions: Our findings that genetic variants of genes involved in asthma and 49
COPD are associated with lung function decline in normal aging subjects suggest that 50 similar genetic mechanisms may underlie lung function decline in both disease and 51 normal aging processes. 52
INTRODUCTION 54
For healthy non-smokers, the forced expiratory volume in 1 second (FEV 1 ), 55 increases from birth and reaches its peak at around the ages of 20 and 25 years (the 56 growth phase), it remains stable until the ages of 30 to 35 years (the plateau phase), 57 and begins to decline with aging (the decline phase)(1-3). In the elderly, low lung 58 function is associated with impaired cognitive function, reduced physical activity and all-59 cause mortality(4-6). Since a substantial proportion of the general population has 60 unrecognized low lung function, its impact on health and quality of life can easily be 61
underestimated(7). 62
Segregation studies have suggested a genetic contribution to lung function 63 variability in the general population(8, 9). Linkage(10-12) and association(13-15) 64 studies further attempted to localize the genetic loci influencing lung function. Since low 65 lung function is a feature of uncontrolled asthma and COPD, we hypothesized that 66 genetic variants that predispose to asthma and COPD might underlie the rapidity of lung 67 function decline. We conducted a longitudinal lung function study in a cohort of men 68 with available DNA and over 25 years of lung function data to determine if 69 polymorphisms of asthma and COPD candidate genes are determinants of lung function 70 decline in a healthy aging population. 71
METHODS 73
The study cohort was a subset of the original Normative Aging Study (NAS) function decline defined as the change in forced expiratory volume in 1 second (FEV 1 ) 88 between two consecutive visits over the number of years between the two visits: 89 ΔFEV 1 = (FEV 1 at visit n+1 -FEV 1 at visit n ) / (age at visit n+1 -age at visit n ), 90 where n is visit number (1 ≤ n ≤ 13). 91
Candidate genes were selected based on their known or suspected roles in the 92 pathogeneses of asthma and COPD, from review of the existing literature performed by 93 2 of the authors (AHP and AAL). In particular, they are genes which have been 94 identified to be asthma or asthma-related phenotype genes through positional cloning orcandidate gene association testing. SNPs in 19 candidate genes were selected for 96 investigation if they were either (1) tagging SNPs with r 2 < 0.80 and minor allele 97 frequency > 5%, covering 5kb upstream and downstream of the first and last exons of 98 each gene, (2) non-synonymous amino acid change with minor allele frequency > 1% or 99 (3) known associated variants with asthma, COPD, and related phenotypes. 100
Genotyping of SNPs for the screening cohort was carried out using the Illumina 101 BeadStation 500G (San Diego, CA, USA). Genotyping for the replication cohort was 102 carried out using one of two platforms, the Sequenom MassArray MALDI-TOF mass 103 spectrometer (Sequenom, CA, USA) and the TaqMan 5' exonuclease assays (Applied 104
Biosystems, CA, USA)(21). Details of genotyping are provided in the Supplementary 105
Material. 106
A two-stage testing -replication strategy was adopted where the study population 107 was divided into 2 subsets: a testing cohort (TC) and a replication cohort (RC). The 108 entire SNP set was tested for associations between individual SNP and lung function 109 decline in TC in the presence of potential confounders (height, age, smoking status, and 110 intensity of cigarette smoking in pack-years). Mixed models were implemented in the 111
Mixed Procedure in SAS (SAS Institute, Inc., Cary, NC), using the "Repeated" statement 112 to account for correlations between repeated observations on each subject. Further 113 details of statistical methods can be found in the Supplementary Material. SNPs 114 associated in the TC at p ≤ 0.1 under either additive or recessive models were 115 genotyped in RC. Associated SNPs were tested by the same statistical method and 116
under the same genetic model as those observed in TC. Analyses in RC were 117 constrained to having the same direction of effect as in TC, thus one-sided testing wasemployed in the RC. Due to the consistency in direction between associations in TC 119 and RC, two-sided P-values from TC and one-sided P-values from RC were combined 120 using Fisher's method(22). Bonferroni correction was applied to adjust the p-values. 121
Population stratification was assessed using PLINK(see Supplementary material)(23). 122
RESULTS

124
Population characteristics 125
The study sample consisted of 1047 subjects, who had DNA samples, smoking 126 history and lung function data, and were randomly divided into 545 and 502 subjects for 127 TC and RC, respectively. The two cohorts were comparable in demographic, lung 128 function and smoking characteristics (Table 1) . At baseline, the mean age was 41. 
SNP Associations 138
A total of 943 SNPs from 44 candidate genes were genotyped and analyzed in 139 the TC under both additive and recessive models (see Supplementary Material, Table  140 S1). Genotyping success rates of > 90% were achieved for all but 13 SNPs. These 13 141
SNPs were excluded from subsequent analyses. A total of 194 SNPs were associated 142 with change in FEV 1 at p-value ≤ 0.1. Twenty-four of the 194 SNPs were associated 143 under both additive and recessive models, and the association under the recessive 144 model for all the 24 SNPs were more statistically significant, hence for these 24 SNPs, 145
only the recessive model was tested in the RC. After removal of 11 SNPs that were outof Hardy Weinberg equilibrium, a total of 119 SNPs were successfully genotyped and 147 analyzed in the replication cohort. Forty-four SNPs were found to have the same 148 direction of effect in both the TC and RC, and evidence for association was combined. 149 A total of 13 SNPs remained statistically significant for their association with decline in 150 FEV 1 , after Bonferroni adjustment (Table S4) . 151 Table 2 In addition, the same variants were also tested for association with rates of FVC 162 decline (Table 3) , defined in a similar way as for FEV 1 decline. Five of the 13 FEV 1 163 decline associated SNPs (rs177836, rs958457 and rs484938 of DPP10 and rs117714 164 of NPSR1 and rs543749 of ADAM33) were associated with rate of FVC decline 165 (p<0.05). Variants of DPP10 and ADAM33 were significantly associated with rate of 166 FVC decline in the same direction as that observed for rate of FEV 1 decline where 167 homozygotes of the rare allele confer a slower rate of FEV 1 and FVC 1 decline. On the 168 contrary, variant rs117714 of NPRS1 was significantly associated with both FEV 1 andFVC decline, but in the opposite direction. The rare homozygote of NPRS1 rs117714 170 confers a slower rate of FEV 1 decline but the same genotype confers a faster rate of 171 decline in FVC. 172
Discussion 173
We conducted a candidate gene analysis and report genetic variants influencing 174 lung function decline in a general population sample of men that was initially recruited to 175 study healthy aging. Findings of genetic association with lung function decline in 176 general populations have been reported using longitudinal data(14, 15), yet the number 177 of candidate genes and their SNPs investigated were limited. To date, only one 178 genome-wide study of lung function decline has been published and that study had no 179 findings that reached genome-wide statistical significance(24). However, in that study, 180 the longest mean follow-up time was only 14.6 yrs (±7.2 yrs), and most of the cohorts 181 only had 2 lung function measures. The strength of this study derives from the 182 availability of multiple, repeated lung function and predictor information gathered over a 183 mean of 25 years, allowing us to account for changes in exposures (i.e. age and 184 smoking) over time. 185
We found DPP10, NPRS1, VDR and ADAM33 to be associated with lung 186 function decline and these genes have all been shown to be associated with asthma in 187 multiple populations; ADAM33 was implicated as an asthma gene in 17 populations, 188 DPP10 in 4 VDR in 6 and GPR154 in 9, as summarized in Michel et al(25) . In our 189 study, the associated variant ADAM33 rs542749, also known as V-1, has been found to 190 be associated with asthma(26) and atopy(27). Furthermore, rs543749 has been found 191 In addition to ADAM33 and DPP10, neuropeptide S receptor 1 (NPRS1), also 211 known as G-protein receptor 154 (GPR154) is the third asthma gene discovered 212 through positional cloning and found to be associated with rates of FEV 1 decline in our 213 study. NPRS1 has been shown, when activated by its endogeneous agonist 214 neuropeptide S, to increase cAMP and Ca 2+ levels(32) and its mRNA expression profile 215 suggests a role in modulating macrophage and eosinophils immune responses(33). 216
Furthermore, mRNA expression of NPRS1 has been found to be elevated in the ciliated 217 cells of the airway epithelium of asthmatic subjects compared to controls, suggesting arole of NPRS1 in airway defense(34).. Polymorphisms of NPRS1 have been found to 219 be associated with asthma or related phenotypes (e.g. IgE, airway responsiveness) in 220 several populations (34) (35) (36) . A total of 4 variants were found to be associated with rates 221 of FEV 1 decline in this study. Homozygotes of the rare alleles for all variants confer a 222 slower rate of FEV 1 decline. Of the 4 associated variants, rs323917 has previously 223 been shown to be associated with airway hyperresponsiveness, with the rare allele 224 associated with increased airway hyperresponsiveness(35). Immunocytochemistry 225 staining of bronchial biopsy tissue of asthmatic and non-asthmatic subjects has shown 226 that NPRS1 protein is expressed in bronchial epithelium cells of asthmatic and not in 227 control subjects(37). Furthermore, the expression of tenascin C mRNA has been 228 shown to be regulated by NPS, the ligand of NPSR1, suggesting that NPRS1 may 229 mediate lung function via tenascin C, an extracellular matrix protein expressed during 230
inflammation(37). 231
One variant of SFTPD, MMP12, VDR and TGFB1 have been found to be 232 associated with rate of FEV 1 decline in our study. Genetic variants of SFTPD and 233 MMP12 have been found to be associated with COPD, lung function and/or asthma (38) . 234 The minor allele (T) of variant rs7078012 of SFTPD was associated with a faster rate of 235 FEV 1 decline in our study, and the same allele was observed to be associated with two 236 cohorts of COPD(39), with a protective effect. Variant rs17099726 resides around 6kb 237 upstream of MMP12 and upstream of the functional variant rs2276109, which has been 238 shown to be associated with lung function in asthmatic children and adults who smoke; 239 and with development of COPD in the NAS population(38). However, in the general 240 population of non-COPD subjects, the functional variant rs2276109 was not associatedwith lung function decline. At present, the biological function of rs17099726 is unknown. 242
Noteworthy is the location of the associated variants of VDR and TGFB1, which are 243 mapped onto intronic region of nearby genes. Variant rs12368284 is located upstream 244 of exon 1f of VDR and in an intronic region towards the 3' end of the collagen type II, 245 alpha 1 (COL2A1) gene; similarly variant rs10417924 resides in a LD block spanning 246 between 3' end of TGFB1 and the entire coiled-coil domain containing 97 (CCDC97) 247 gene. Given the gene-level replications observed between variants of TGFB1 and 248
COPD, the effect of this variant is likely mediated through TGFB1(40). 249
In addition to rates of FEV 1 decline, 6 of the 13 variants also showed significant 250 association with rates of FVC decline, suggesting that the mechanisms which DPP10, 251 NPRS1 and ADAM33 operated under affect rates of lung function decline potentially 252 through both airway caliber and lung volume. 253
This study has its limitations. Since the cohort is composed of Caucasian men, 254 associations detected in this cohort may not be generalizable to women and non-255
Caucasians. In addition, since the mean age of this cohort at baseline was 41 years, 256 genetic factors which we have identified to influence lung function decline may not be 257 the same as those that influence growth in younger populations. Because genotyping 258 for this project began several years ago, we were unable to include variants from genes 259 that have recently been associated with asthma (e.g. ORMDL3, PDE4D), COPD 260 (CHRNA 3/5), or lung function (GSTO2 and IL6R). Nevertheless, our findings that 261 genetic variants of genes involved in asthma and COPD pathogenesis are associated 262 with lung function decline in normal aging subjects suggest that similar genetic 263 mechanisms underlie lung function decline in both disease and normal aging processes.
While longitudinal studies are generally thought to provide more accurate estimates of 265 lung function decline, these types of studies also have problems such as learning 266 effects, loss to follow-up, variability over time of spirometers and technicians. We have 267 attempted to minimize these effects where possible. While spirometry was performed in 268 a standardized manner from the inception of the study in the 1960s(17), standardization 269 was modified beginning in 1984 to comply with the recommendations from the ATS (18), 270 and a different spirometer was used. We attempted to account for this change by 271 creating a variable that identified the method and adjusted this in our analyses. While 272 the standardization method itself was a significant determinant of lung function decline, 273 it did not affect the observed associations between the SNPs and lung function decline, 274
whether the variable was in the model or not. Additionally, we used standardized 275 protocols for measuring spirometry to minimize variability between technicians. 276
In summary, we have found that variants in 7 asthma and COPD candidate 277 
